8-K: Coherus BioSciences Finalizes Sale of Ophthalmology Franchise to Sandoz for $187.8 Million

Coherus BioSciences has completed the divestiture of its ophthalmology franchise, including CIMERLI, to Sandoz for $170 million in upfront cash, plus $17.8 million for inventory and prepaid assets.

Summary

• Coherus BioSciences has completed the sale of its ophthalmology business, including the drug CIMERLI, to Sandoz for a total of $187.8 million.
• The deal includes $170 million in upfront cash, plus $17.8 million for CIMERLI product inventory and prepaid manufacturing assets.
• This divestiture allows Coherus to focus on its oncology business, pay down debt, and reduce operating costs.
• As part of the transaction, Coherus will make a $175 million partial prepayment on its existing loan, plus a $6.8 million prepayment premium.
• The company also released pro forma financial information reflecting the divestiture and the previous acquisition of Surface Oncology.

Sentiment

Score: 7

Explanation: The document is generally positive due to the successful divestiture and debt reduction, but there are risks and uncertainties associated with the company's future performance and the pro forma losses.

Positives

• The divestiture provides a significant cash infusion of $187.8 million.
• The company will reduce its debt by $175 million, improving its financial position.
• The sale allows Coherus to focus on its core oncology business.
• The company expects to reduce headcount and overhead costs.
• The transaction includes the transfer of the CIMERLI biologics license application, sales teams, and commercial software.

Negatives

• The company will incur a $6.8 million prepayment premium and make-whole amount on its debt.
• The pro forma financial statements show a net loss for both the nine months ended September 30, 2023 and the year ended December 31, 2022.
• The company will lose the revenue stream from the ophthalmology franchise.

Risks

• The actual gain on the disposition may differ significantly from the pro forma estimate.
• The company faces risks and uncertainties inherent in the clinical drug development process.
• There are risks related to existing and potential collaboration partners.
• The company faces risks of the drug development position of competitors.
• The company faces risks and uncertainties of the regulatory approval process.
• There is a risk that Coherus is unable to complete commercial transactions.
• There is a risk of possible litigation.

Future Outlook

Coherus will focus on its oncology pipeline, including the launch of LOQTORZI and UDENYCA ONBODY, and expects to become a sustainable and growing oncology business. The company plans to file an IND for CHS-1000 in the first half of 2024.

Management Comments

• Denny Lanfear, Chairman and Chief Executive Officer of Coherus, stated that the transaction sharpens the focus of the business as they advance their novel immuno-oncology pipeline.
• He also mentioned that the completion of the transaction allows them to pay down debt, reduce interest costs, reduce headcount and overhead costs, thereby significantly advancing their efforts to become a sustainable and growing oncology business.

Industry Context

This divestiture reflects a strategic shift for Coherus, moving away from ophthalmology and focusing on the higher-growth potential of the oncology market. This is a common trend in the biopharmaceutical industry, where companies often streamline their portfolios to concentrate on core therapeutic areas.

Comparison to Industry Standards

• The divestiture of a non-core asset to focus on a core business is a common strategy in the pharmaceutical industry, similar to how companies like Pfizer have divested non-core assets to focus on their core therapeutic areas.
• The $187.8 million sale price is a significant amount for a single franchise, but the value is dependent on the future revenue potential of the CIMERLI product and the associated assets.
• The debt reduction strategy is similar to other companies that have used asset sales to improve their balance sheets, such as Teva Pharmaceutical Industries.
• The focus on immuno-oncology is in line with the industry trend towards developing novel cancer therapies, with companies like Bristol Myers Squibb and Merck leading in this space.

Stakeholder Impact

• Shareholders will benefit from the debt reduction and focus on oncology.
• Employees may experience changes due to headcount reductions.
• Customers of the ophthalmology franchise will now be served by Sandoz.
• Creditors will receive a partial repayment of the outstanding loan.

Next Steps

• Coherus will make a partial prepayment of $175 million on its existing loan on or before April 1, 2024.
• The company will continue to advance its immuno-oncology pipeline.
• Coherus plans to file an IND for CHS-1000 in the first half of 2024.
• The company will finalize certain purchase price adjustments related to the divestiture.

Key Dates

Keywords

Coherus BioSciences, Sandoz, CIMERLI, Ophthalmology, Divestiture, Oncology, Debt Reduction, Financial Results, Acquisition, Surface Oncology